Fonte: Ecancermedicalscience. Unidade: FM
Assuntos: NEUROENDOCRINOLOGIA, CARCINOMA NEUROENDÓCRINO, NEOPLASIAS, METFORMINA
ABNT
GLASBERG, Joao et al. METNET: a phase II trial of metformin in patients with well-differentiated neuroendocrine tumours. Ecancermedicalscience, v. 16, 2022Tradução . . Disponível em: https://doi.org/10.3332/ecancer.2022.1369. Acesso em: 12 nov. 2024.APA
Glasberg, J., Talans, A., Giollo, T. R., Recchimuzzi, D. Z., Bezerra Neto, J. E., Lopez, R. V. M., et al. (2022). METNET: a phase II trial of metformin in patients with well-differentiated neuroendocrine tumours. Ecancermedicalscience, 16. doi:10.3332/ecancer.2022.1369NLM
Glasberg J, Talans A, Giollo TR, Recchimuzzi DZ, Bezerra Neto JE, Lopez RVM, Hoff PMG, Riechelmann RP. METNET: a phase II trial of metformin in patients with well-differentiated neuroendocrine tumours [Internet]. Ecancermedicalscience. 2022 ; 16[citado 2024 nov. 12 ] Available from: https://doi.org/10.3332/ecancer.2022.1369Vancouver
Glasberg J, Talans A, Giollo TR, Recchimuzzi DZ, Bezerra Neto JE, Lopez RVM, Hoff PMG, Riechelmann RP. METNET: a phase II trial of metformin in patients with well-differentiated neuroendocrine tumours [Internet]. Ecancermedicalscience. 2022 ; 16[citado 2024 nov. 12 ] Available from: https://doi.org/10.3332/ecancer.2022.1369